Abstract: The invention provides formulations and structural modifications for phenothiazine compounds which result in altered biodistributions, thereby reducing the occurrence of adverse reactions associated with this class of drug.

Abstract: The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient pentamidine or a pentamidine analog and an antiproliferative agent simultaneously or within 14 days of each other in amounts sufficient to treat the patient.

Abstract: The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient two compounds simultaneously or within 14 days of each other in amounts sufficient to treat the patient.

Abstract: The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

Abstract: The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

Abstract: The invention features methods and compositions for treating a patient diagnosed with, or at risk for developing, a fungal infection.

Abstract: The invention features a pharmaceutical composition that includes amoxapine and a corticosteroid.

Abstract: The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient two compounds simultaneously or within 14 days of each other in amounts sufficient to treat the patient.

Abstract: The invention features methods and compositions for the treatment of immunonflammatory disorders.

Abstract: The invention features a method for treating a patient having a cancer or other neoplasm, by administering to the patient (i) a benzimidazole or a metabolite or analog thereof; and (ii) pentamidine or a metabolite or analog thereof simultaneously or within 14 days of each other in amounts sufficient to inhibit the growth of the neoplasm.

Abstract: The invention features a method for treating a patient having a cancer or other neoplasm, by administering to the patient (i) a benzimidazole or a metabolite or analog thereof; and (ii) pentamidine or a metabolite or analog thereof simultaneously or within 14 days of each other in amounts sufficient to inhibit the growth of the neoplasm.

Abstract: The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient two compounds simultaneously or within 14 days of each other in amounts sufficient to treat the patient.

Abstract: The invention features a method for treating a patient having an immunoinflammatory disorder, by administering to the patient (i) a tetra-substituted pyrimidopyrimidine, and (ii) a corticosteroid simultaneously or within 14 days of each other in amounts sufficient to reduce or inhibit immunoinflammation.

Abstract: The invention features a method for treating a patient having a cancer or other neoplasm, by administering to the patient (i) chlorpromazine or a metabolite or analog thereof; and (ii) pentamidine or a metabolite or analog thereof simultaneously or within 14 days of each other in amounts sufficient to inhibit the growth of the neoplasm.

Abstract: The invention features a method of screening for drug-drug interactions using combinational arrays. The method includes the steps of: (a) providing (i) a test drug; (ii) a drug library; and (iii) an assay, (b) contacting the test drug and at least some of the library drugs from the drug library in the assay under conditions that ensure that each test drug/library drug contacting is segregated from the others, (c) recording the result of the contacting of the test drug and the library drug in the assay, and (d) identifying combinations of drugs that produce a result in the assay that is different from the results produced by either drug of the combination by itself. According to the method, each of the identified combinations indicates an interaction between the test drug and the library drug.

Abstract: The invention features a method for treating a patient having an inflammatory disorder, by administering to the patient (i) a tricyclic antidepressant (e.g., amoxapine); and (ii) a corticosteroid (e.g., prednisolone) simultaneously or within 14 days of each other in amounts sufficient to reduce or inhibit inflammation.

Abstract: The invention features a method for treating a patient having a cancer or other neoplasm, by administering to the patient (i) a benzimidazole or a metabolite or analog thereof; and (ii) pentamidine or a metabolite or analog thereof simultaneously or within 14 days of each other in amounts sufficient to inhibit the growth of the neoplasm.

Abstract: A navigational system and a computer-based datalogger are used to store data on the distances traveled by and places visited by a monitored vehicle. The datalogger includes a clock and an on-board memory that can store time-stamped records of the latitude and longitude of places visited by the vehicle. In some such systems the vehicle operator can assign a label or a location classification to selected places that he or she visits. Additionally, in some versions of the system an administrator can use a central computer located at the vehicle's home base to assign labels to locations where the vehicle is expected to make a stop. The central computer generates a map-like graphical output that displays a point corresponding to each of the places visited. This display may also show the time spent at each place visited during an operational period.

Abstract: A navigational system and a computer-based datalogger are used to store data on the distances traveled by and places visited by a monitored vehicle. The datalogger includes a clock and an on-board memory that can store time-stamped records of the latitude and longitude of places visited by the vehicle. In some such systems the vehicle operator can assign a label or a location classification to selected places that he or she visits. Additionally, in some versions of the system an administrator can use a central computer located at the vehicle's home base to assign labels to locations where the vehicle is expected to make a stop. The central computer generates a map-like graphical output that displays a point corresponding to each of the places visited. This display may also show the time spent at each place visited during an operational period.

Abstract: In a fixed wireless terminal (200), a transceiver (210) is coupled to a call processor (208), wherein the call processor (208) includes status information (218). A telephone line coupling (202) is coupled to the call processor (208). A status processor (212) is coupled to the call processor (208) for reading the status information (218). A signaling generator (206) is coupled to the status processor (208) and the telephone line coupling (202) for providing signals that represent the status information (218). Such status information (218) includes operating conditions and test results in the fixed wireless terminal. Such signals include caller ID-type signals and other audio signals. Caller ID signals may be displayed on a caller ID module (222) or a caller ID equipped telephone. A request for status information (218) may be entered at a telephone (220) connected to the fixed wireless terminal (200).